CL2016000677A1 - Compuestos derivados de etinilo, moduladores alostericos positivos del receptor mglur4; composicion farmaceutica que los comprende; y su uso en enfermedades del snc, cancer y diabetes tipo 2. - Google Patents
Compuestos derivados de etinilo, moduladores alostericos positivos del receptor mglur4; composicion farmaceutica que los comprende; y su uso en enfermedades del snc, cancer y diabetes tipo 2.Info
- Publication number
- CL2016000677A1 CL2016000677A1 CL2016000677A CL2016000677A CL2016000677A1 CL 2016000677 A1 CL2016000677 A1 CL 2016000677A1 CL 2016000677 A CL2016000677 A CL 2016000677A CL 2016000677 A CL2016000677 A CL 2016000677A CL 2016000677 A1 CL2016000677 A1 CL 2016000677A1
- Authority
- CL
- Chile
- Prior art keywords
- diabetes
- cancer
- type
- ethynyl
- cns
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
Se describen compuestos de fórmula I. Se describen además las composiciones farmacéuticas que los comprenden; y uso de los compuestos para preparar un medicamento útil en el tratamiento de la enfermedad de Parkinson, la ansiedad, la emesis, el trastorno obsesivo-compulsivo, el autismo, la neuroprotección, el cáncer, la depresión y la diabetes de tipo 2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13185856 | 2013-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2016000677A1 true CL2016000677A1 (es) | 2016-11-04 |
Family
ID=49230629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016000677A CL2016000677A1 (es) | 2013-09-25 | 2016-03-23 | Compuestos derivados de etinilo, moduladores alostericos positivos del receptor mglur4; composicion farmaceutica que los comprende; y su uso en enfermedades del snc, cancer y diabetes tipo 2. |
Country Status (28)
Country | Link |
---|---|
US (2) | US20160207890A1 (es) |
EP (1) | EP3049409B1 (es) |
JP (1) | JP6134441B2 (es) |
KR (1) | KR101757603B1 (es) |
CN (1) | CN105579447B (es) |
AR (1) | AR097721A1 (es) |
AU (1) | AU2014327504B2 (es) |
BR (1) | BR112016005994A2 (es) |
CA (1) | CA2924376A1 (es) |
CL (1) | CL2016000677A1 (es) |
CR (1) | CR20160075A (es) |
DK (1) | DK3049409T3 (es) |
EA (1) | EA029352B1 (es) |
ES (1) | ES2630319T3 (es) |
HK (1) | HK1220200A1 (es) |
HU (1) | HUE034849T2 (es) |
IL (1) | IL244039B (es) |
MA (1) | MA38885B1 (es) |
MX (1) | MX370341B (es) |
MY (1) | MY183953A (es) |
PE (1) | PE20160666A1 (es) |
PH (1) | PH12016500427A1 (es) |
PL (1) | PL3049409T3 (es) |
SG (1) | SG11201602029VA (es) |
SI (1) | SI3049409T1 (es) |
TW (1) | TWI527801B (es) |
UA (1) | UA116277C2 (es) |
WO (1) | WO2015044075A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA029261B1 (ru) * | 2014-02-25 | 2018-02-28 | Ф. Хоффманн-Ля Рош Аг | Производные этинила |
JP6539749B2 (ja) * | 2015-03-19 | 2019-07-03 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | mGluR4のモジュレーターとしての3−(4−エチニルフェニル)ヘキサヒドロピリミジン−2,4−ジオン誘導体 |
KR20180026438A (ko) | 2015-07-15 | 2018-03-12 | 에프. 호프만-라 로슈 아게 | 대사형 글루타메이트 수용체 조절제로서의 에틴일 유도체 |
AR105556A1 (es) * | 2015-08-03 | 2017-10-18 | Hoffmann La Roche | Derivados de etinilo |
US10308656B2 (en) | 2015-08-18 | 2019-06-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of Ku70/80 and uses thereof |
ES2826389T3 (es) * | 2016-07-18 | 2021-05-18 | Hoffmann La Roche | Derivados de etinilo |
CA3102326A1 (en) | 2018-07-26 | 2020-01-30 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10330359A (ja) * | 1997-03-31 | 1998-12-15 | Nippon Bayeragrochem Kk | フエニルアセチレン誘導体及び除草剤 |
GB0503646D0 (en) * | 2005-02-22 | 2005-03-30 | Novartis Ag | Organic compounds |
MX2009013169A (es) * | 2007-06-03 | 2010-04-30 | Univ Vanderbilt | Moduladores alostericos positivos del mglur5 benzamida y metodos de elaboracion y uso de los mismos. |
US8779157B2 (en) * | 2009-09-04 | 2014-07-15 | Vanderbilt University | MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
CA2789434A1 (en) * | 2010-02-11 | 2011-08-18 | Vanderbilt University | Benzisoxazoles and azabenzisoxazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
KR20130079429A (ko) * | 2010-05-12 | 2013-07-10 | 벤더르빌트 유니버시티 | 헤테로시클릭 설폰 mglur4 알로스테릭 강화제, 조성물 및 신경 기능이상을 치료하는 방법 |
UA110862C2 (uk) * | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
CN102503888A (zh) * | 2011-10-08 | 2012-06-20 | 西安交通大学 | 2-芳基-1,3-异喹啉二酮类抗肿瘤化合物及其合成方法和用途 |
-
2014
- 2014-09-22 MX MX2016002717A patent/MX370341B/es active IP Right Grant
- 2014-09-22 SI SI201430272T patent/SI3049409T1/sl unknown
- 2014-09-22 WO PCT/EP2014/070100 patent/WO2015044075A1/en active Application Filing
- 2014-09-22 HU HUE14781474A patent/HUE034849T2/en unknown
- 2014-09-22 EP EP14781474.3A patent/EP3049409B1/en active Active
- 2014-09-22 MY MYPI2016000532A patent/MY183953A/en unknown
- 2014-09-22 PL PL14781474T patent/PL3049409T3/pl unknown
- 2014-09-22 KR KR1020167007447A patent/KR101757603B1/ko active IP Right Grant
- 2014-09-22 UA UAA201604513A patent/UA116277C2/uk unknown
- 2014-09-22 AR ARP140103499A patent/AR097721A1/es unknown
- 2014-09-22 CN CN201480052343.0A patent/CN105579447B/zh active Active
- 2014-09-22 EA EA201690408A patent/EA029352B1/ru not_active IP Right Cessation
- 2014-09-22 DK DK14781474.3T patent/DK3049409T3/en active
- 2014-09-22 CA CA2924376A patent/CA2924376A1/en not_active Abandoned
- 2014-09-22 PE PE2016000237A patent/PE20160666A1/es active IP Right Grant
- 2014-09-22 JP JP2016517337A patent/JP6134441B2/ja active Active
- 2014-09-22 SG SG11201602029VA patent/SG11201602029VA/en unknown
- 2014-09-22 AU AU2014327504A patent/AU2014327504B2/en not_active Ceased
- 2014-09-22 BR BR112016005994A patent/BR112016005994A2/pt not_active Application Discontinuation
- 2014-09-22 ES ES14781474.3T patent/ES2630319T3/es active Active
- 2014-09-22 MA MA38885A patent/MA38885B1/fr unknown
- 2014-09-23 TW TW103132854A patent/TWI527801B/zh not_active IP Right Cessation
-
2016
- 2016-02-09 IL IL244039A patent/IL244039B/en not_active IP Right Cessation
- 2016-02-16 CR CR20160075A patent/CR20160075A/es unknown
- 2016-03-04 PH PH12016500427A patent/PH12016500427A1/en unknown
- 2016-03-23 CL CL2016000677A patent/CL2016000677A1/es unknown
- 2016-03-25 US US15/081,573 patent/US20160207890A1/en not_active Abandoned
- 2016-07-15 HK HK16108345.7A patent/HK1220200A1/zh unknown
- 2016-09-30 US US15/283,010 patent/US9676732B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016000677A1 (es) | Compuestos derivados de etinilo, moduladores alostericos positivos del receptor mglur4; composicion farmaceutica que los comprende; y su uso en enfermedades del snc, cancer y diabetes tipo 2. | |
NI201600164A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
CL2016001595A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6. | |
CL2014003388A1 (es) | Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades. | |
CL2015002123A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
CL2013003731A1 (es) | Compuestos derivados de carboxamida; composición farmacéutica que los comprende, y su uso como inhibidores de la fosfodiesterasa tipo 10a (pde10a) para el tratamiento de trastornos del snc, esquizofrenia, disfunción cognitiva relacionada con la esquizofrenia, trastornos bipolares, depresión, disfunción cognitiva, alteraciones cognitivas, trastornos del comportamiento asociados a la enfermedad de alzheimer, obesidad, enfermedad de huntington y ansiedad. | |
NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
CL2014000956A1 (es) | Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor. | |
CL2013002517A1 (es) | Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer. | |
CL2015002125A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
DOP2014000115A (es) | Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
UY35210A (es) | Inhibidores de autotaxina | |
CR20160033A (es) | Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromático-bencil-amida | |
ECSP13012573A (es) | 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3 | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
NI201500096A (es) | Compuesto químicos | |
DOP2015000076A (es) | Benzamidas | |
SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
CL2016001739A1 (es) | Trece compuestos específicos derivados de 6,7,8,8a-tetrahidro-5h-imidazol1,5-a-piridin-1,3-diona, moduladores alostéricos positivos map del receptor metabotrópico del glutamato 4 mglur4 composiciones farmacológicas procedimiento de preparación útiles para el tratamiento del parkinson, ansiedad, emesis, trastorno obsesivo-compulsivo, autismo, neuroprotección, cáncer, depresión, esquizofrenia y diabetes tipo 2. |